Adelaide, Australia; Research Site
Lumiliximab with Fludarbine, Cyclophosphamide and Rituximab (FCR) Versus FCR Alone in Subjects with Relapsed Chronic Lymphocytic Leukemia (CLL)
Freemantle, Australia; Research Site
Lumiliximab with Fludarbine, Cyclophosphamide and Rituximab (FCR) Versus FCR Alone in Subjects with Relapsed Chronic Lymphocytic Leukemia (CLL)
Gosford, Australia; Research Site
Lumiliximab with Fludarbine, Cyclophosphamide and Rituximab (FCR) Versus FCR Alone in Subjects with Relapsed Chronic Lymphocytic Leukemia (CLL)
Nedlands, Australia; Research Site
Lumiliximab with Fludarbine, Cyclophosphamide and Rituximab (FCR) Versus FCR Alone in Subjects with Relapsed Chronic Lymphocytic Leukemia (CLL)
St. Leonards, Australia; Research Site
Lumiliximab with Fludarbine, Cyclophosphamide and Rituximab (FCR) Versus FCR Alone in Subjects with Relapsed Chronic Lymphocytic Leukemia (CLL)
Waratah, Australia; Research Site
Lumiliximab with Fludarbine, Cyclophosphamide and Rituximab (FCR) Versus FCR Alone in Subjects with Relapsed Chronic Lymphocytic Leukemia (CLL)
Westmead, Australia; Research Site
Lumiliximab with Fludarbine, Cyclophosphamide and Rituximab (FCR) Versus FCR Alone in Subjects with Relapsed Chronic Lymphocytic Leukemia (CLL)
Woodville, Australia; Research Site
Lumiliximab with Fludarbine, Cyclophosphamide and Rituximab (FCR) Versus FCR Alone in Subjects with Relapsed Chronic Lymphocytic Leukemia (CLL)
Woolloongabba, Australia; Research Site
Lumiliximab with Fludarbine, Cyclophosphamide and Rituximab (FCR) Versus FCR Alone in Subjects with Relapsed Chronic Lymphocytic Leukemia (CLL)
Graz, Austria; Research Site
Lumiliximab with Fludarbine, Cyclophosphamide and Rituximab (FCR) Versus FCR Alone in Subjects with Relapsed Chronic Lymphocytic Leukemia (CLL)
Herston, Austria; Research Site
Lumiliximab with Fludarbine, Cyclophosphamide and Rituximab (FCR) Versus FCR Alone in Subjects with Relapsed Chronic Lymphocytic Leukemia (CLL)
Wien, Austria; Research Site
Lumiliximab with Fludarbine, Cyclophosphamide and Rituximab (FCR) Versus FCR Alone in Subjects with Relapsed Chronic Lymphocytic Leukemia (CLL)
Wien, Austria; Research Site
Lumiliximab with Fludarbine, Cyclophosphamide and Rituximab (FCR) Versus FCR Alone in Subjects with Relapsed Chronic Lymphocytic Leukemia (CLL)
Wien, Austria; Research Site
Lumiliximab with Fludarbine, Cyclophosphamide and Rituximab (FCR) Versus FCR Alone in Subjects with Relapsed Chronic Lymphocytic Leukemia (CLL)
Brugge, Belgium; Research Site
Lumiliximab with Fludarbine, Cyclophosphamide and Rituximab (FCR) Versus FCR Alone in Subjects with Relapsed Chronic Lymphocytic Leukemia (CLL)
Bruxelles, Belgium; Research Site
Lumiliximab with Fludarbine, Cyclophosphamide and Rituximab (FCR) Versus FCR Alone in Subjects with Relapsed Chronic Lymphocytic Leukemia (CLL)
Bruzelles, Belgium; Research Site
Lumiliximab with Fludarbine, Cyclophosphamide and Rituximab (FCR) Versus FCR Alone in Subjects with Relapsed Chronic Lymphocytic Leukemia (CLL)
Edegem, Belgium; Research Site
Lumiliximab with Fludarbine, Cyclophosphamide and Rituximab (FCR) Versus FCR Alone in Subjects with Relapsed Chronic Lymphocytic Leukemia (CLL)
Gent, Belgium; Research Site
Lumiliximab with Fludarbine, Cyclophosphamide and Rituximab (FCR) Versus FCR Alone in Subjects with Relapsed Chronic Lymphocytic Leukemia (CLL)
Yvoir, Belgium; Research Site
Lumiliximab with Fludarbine, Cyclophosphamide and Rituximab (FCR) Versus FCR Alone in Subjects with Relapsed Chronic Lymphocytic Leukemia (CLL)
Edmonton, Canada; Research Site
Lumiliximab with Fludarbine, Cyclophosphamide and Rituximab (FCR) Versus FCR Alone in Subjects with Relapsed Chronic Lymphocytic Leukemia (CLL)
London, Canada; Research Site
Lumiliximab with Fludarbine, Cyclophosphamide and Rituximab (FCR) Versus FCR Alone in Subjects with Relapsed Chronic Lymphocytic Leukemia (CLL)
Montreal, Canada; Research Site
Lumiliximab with Fludarbine, Cyclophosphamide and Rituximab (FCR) Versus FCR Alone in Subjects with Relapsed Chronic Lymphocytic Leukemia (CLL)
Brno, Czech Republic; Research Center
If the patient has B-Cell Chronic Lymphocytic Leukemia, has failed treatment with fludarabine, and failed or been intolerant ineligible to treatment with alemtuzumab, he/she may be eligible for this clinical trial.
Hradec Kralove, Czech Republic; Research Center
If the patient has B-Cell Chronic Lymphocytic Leukemia, has failed treatment with fludarabine, and failed or been intolerant ineligible to treatment with alemtuzumab, he/she may be eligible for this clinical trial.
Plzen, Czech Republic; Research Center
If the patient has B-Cell Chronic Lymphocytic Leukemia, has failed treatment with fludarabine, and failed or been intolerant ineligible to treatment with alemtuzumab, he/she may be eligible for this clinical trial.
Prague, Czech Republic; Research Center
If the patient has B-Cell Chronic Lymphocytic Leukemia, has failed treatment with fludarabine, and failed or been intolerant ineligible to treatment with alemtuzumab, he/she may be eligible for this clinical trial.
Prague, Czech Republic; Research Center
If the patient has B-Cell Chronic Lymphocytic Leukemia, has failed treatment with fludarabine, and failed or been intolerant ineligible to treatment with alemtuzumab, he/she may be eligible for this clinical trial.
Copenhagen, Denmark; Research Center
If the patient has B-Cell Chronic Lymphocytic Leukemia, has failed treatment with fludarabine, and failed or been intolerant ineligible to treatment with alemtuzumab, he/she may be eligible for this clinical trial.
Odense, Denmark; Research Site
If the patient has B-Cell Chronic Lymphocytic Leukemia, has failed treatment with fludarabine, and failed or been intolerant ineligible to treatment with alemtuzumab, he/she may be eligible for this clinical trial.
Vejle, Denmark; Research Site
If the patient has B-Cell Chronic Lymphocytic Leukemia, has failed treatment with fludarabine, and failed or been intolerant ineligible to treatment with alemtuzumab, he/she may be eligible for this clinical trial.
Angers, France; Research Site
Lumiliximab with Fludarbine, Cyclophosphamide and Rituximab (FCR) Versus FCR Alone in Subjects with Relapsed Chronic Lymphocytic Leukemia (CLL)
Bordeaux, France; Research Site
Lumiliximab with Fludarbine, Cyclophosphamide and Rituximab (FCR) Versus FCR Alone in Subjects with Relapsed Chronic Lymphocytic Leukemia (CLL)
Le Mans, France; Research Site
Lumiliximab with Fludarbine, Cyclophosphamide and Rituximab (FCR) Versus FCR Alone in Subjects with Relapsed Chronic Lymphocytic Leukemia (CLL)
Limoges, France; Research Site
Lumiliximab with Fludarbine, Cyclophosphamide and Rituximab (FCR) Versus FCR Alone in Subjects with Relapsed Chronic Lymphocytic Leukemia (CLL)
Lyon, France; Research Center
If the patient has B-Cell Chronic Lymphocytic Leukemia, has failed treatment with fludarabine, and failed or been intolerant ineligible to treatment with alemtuzumab, he/she may be eligible for this clinical trial.
Nice, France; Research Site
Lumiliximab with Fludarbine, Cyclophosphamide and Rituximab (FCR) Versus FCR Alone in Subjects with Relapsed Chronic Lymphocytic Leukemia (CLL)
Paris, France; Research Center
If the patient has B-Cell Chronic Lymphocytic Leukemia, has failed treatment with fludarabine, and failed or been intolerant ineligible to treatment with alemtuzumab, he/she may be eligible for this clinical trial.
Pierre Bénite, France; Research Center
If the patient has B-Cell Chronic Lymphocytic Leukemia, has failed treatment with fludarabine, and failed or been intolerant ineligible to treatment with alemtuzumab, he/she may be eligible for this clinical trial.
Rouen, France; Research Site
If the patient has B-Cell Chronic Lymphocytic Leukemia, has failed treatment with fludarabine, and failed or been intolerant ineligible to treatment with alemtuzumab, he/she may be eligible for this clinical trial.
Vandoeuvre les Nancy, France; Research Center
If the patient has B-Cell Chronic Lymphocytic Leukemia, has failed treatment with fludarabine, and failed or been intolerant ineligible to treatment with alemtuzumab, he/she may be eligible for this clinical trial.
Dresden, Germany; Research Center
If the patient has B-Cell Chronic Lymphocytic Leukemia, has failed treatment with fludarabine, and failed or been intolerant ineligible to treatment with alemtuzumab, he/she may be eligible for this clinical trial.
Essen, Germany; Research Center
If the patient has B-Cell Chronic Lymphocytic Leukemia, has failed treatment with fludarabine, and failed or been intolerant ineligible to treatment with alemtuzumab, he/she may be eligible for this clinical trial.
Frankfurt, Germany; Research Center
If the patient has B-Cell Chronic Lymphocytic Leukemia, has failed treatment with fludarabine, and failed or been intolerant ineligible to treatment with alemtuzumab, he/she may be eligible for this clinical trial.
Hamburg, Germany; Research Center
If the patient has B-Cell Chronic Lymphocytic Leukemia, has failed treatment with fludarabine, and failed or been intolerant ineligible to treatment with alemtuzumab, he/she may be eligible for this clinical trial.
Homburg/Saar, Germany; Research Center
If the patient has B-Cell Chronic Lymphocytic Leukemia, has failed treatment with fludarabine, and failed or been intolerant ineligible to treatment with alemtuzumab, he/she may be eligible for this clinical trial.
Kiel, Germany; Research Center
If the patient has B-Cell Chronic Lymphocytic Leukemia, has failed treatment with fludarabine, and failed or been intolerant ineligible to treatment with alemtuzumab, he/she may be eligible for this clinical trial.
Mainz, Germany; Research Center
If the patient has B-Cell Chronic Lymphocytic Leukemia, has failed treatment with fludarabine, and failed or been intolerant ineligible to treatment with alemtuzumab, he/she may be eligible for this clinical trial.
Mönchengladback-Rheydt, Germany; Research Center
If the patient has B-Cell Chronic Lymphocytic Leukemia, has failed treatment with fludarabine, and failed or been intolerant ineligible to treatment with alemtuzumab, he/she may be eligible for this clinical trial.
Ulm, Germany; Research Center
If the patient has B-Cell Chronic Lymphocytic Leukemia, has failed treatment with fludarabine, and failed or been intolerant ineligible to treatment with alemtuzumab, he/she may be eligible for this clinical trial.
Bari, Italy; Research Center
If the patient has B-Cell Chronic Lymphocytic Leukemia, has failed treatment with fludarabine, and failed or been intolerant ineligible to treatment with alemtuzumab, he/she may be eligible for this clinical trial.
Bologna, Italy; Research Site
Lumiliximab with Fludarbine, Cyclophosphamide and Rituximab (FCR) Versus FCR Alone in Subjects with Relapsed Chronic Lymphocytic Leukemia (CLL)
Cagliari, Italy; Research Site
Lumiliximab with Fludarbine, Cyclophosphamide and Rituximab (FCR) Versus FCR Alone in Subjects with Relapsed Chronic Lymphocytic Leukemia (CLL)
Milan, Italy; Research Center
If the patient has B-Cell Chronic Lymphocytic Leukemia, has failed treatment with fludarabine, and failed or been intolerant ineligible to treatment with alemtuzumab, he/she may be eligible for this clinical trial.
Milano, Italy; Research Site
Lumiliximab with Fludarbine, Cyclophosphamide and Rituximab (FCR) Versus FCR Alone in Subjects with Relapsed Chronic Lymphocytic Leukemia (CLL)
Roma, Italy; Research Center
If the patient has B-Cell Chronic Lymphocytic Leukemia, has failed treatment with fludarabine, and failed or been intolerant ineligible to treatment with alemtuzumab, he/she may be eligible for this clinical trial.
Rotterdam, Netherlands; Research Center
If the patient has B-Cell Chronic Lymphocytic Leukemia, has failed treatment with fludarabine, and failed or been intolerant ineligible to treatment with alemtuzumab, he/she may be eligible for this clinical trial.
Bialystok, Poland; Research Site
Lumiliximab with Fludarbine, Cyclophosphamide and Rituximab (FCR) Versus FCR Alone in Subjects with Relapsed Chronic Lymphocytic Leukemia (CLL)
Bialystok, Poland; Research Center
If the patient has B-Cell Chronic Lymphocytic Leukemia, has failed treatment with fludarabine, and failed or been intolerant ineligible to treatment with alemtuzumab, he/she may be eligible for this clinical trial.
Gdansk, Poland; Research Site
Lumiliximab with Fludarbine, Cyclophosphamide and Rituximab (FCR) Versus FCR Alone in Subjects with Relapsed Chronic Lymphocytic Leukemia (CLL)
Gdansk, Poland; Research Center
If the patient has B-Cell Chronic Lymphocytic Leukemia, has failed treatment with fludarabine, and failed or been intolerant ineligible to treatment with alemtuzumab, he/she may be eligible for this clinical trial.
Katowice, Poland; Research Center
If the patient has B-Cell Chronic Lymphocytic Leukemia, has failed treatment with fludarabine, and failed or been intolerant ineligible to treatment with alemtuzumab, he/she may be eligible for this clinical trial.
Katowice, Poland; Research Site
Lumiliximab with Fludarbine, Cyclophosphamide and Rituximab (FCR) Versus FCR Alone in Subjects with Relapsed Chronic Lymphocytic Leukemia (CLL)
Krakow, Poland; Research Center
If the patient has B-Cell Chronic Lymphocytic Leukemia, has failed treatment with fludarabine, and failed or been intolerant ineligible to treatment with alemtuzumab, he/she may be eligible for this clinical trial.
Krakow, Poland; Research Site
Lumiliximab with Fludarbine, Cyclophosphamide and Rituximab (FCR) Versus FCR Alone in Subjects with Relapsed Chronic Lymphocytic Leukemia (CLL)
Lodz, Poland; Research Center
If the patient has B-Cell Chronic Lymphocytic Leukemia, has failed treatment with fludarabine, and failed or been intolerant ineligible to treatment with alemtuzumab, he/she may be eligible for this clinical trial.
Lodz, Poland; Research Site
Lumiliximab with Fludarbine, Cyclophosphamide and Rituximab (FCR) Versus FCR Alone in Subjects with Relapsed Chronic Lymphocytic Leukemia (CLL)
Poznan, Poland; Research Center
If the patient has B-Cell Chronic Lymphocytic Leukemia, has failed treatment with fludarabine, and failed or been intolerant ineligible to treatment with alemtuzumab, he/she may be eligible for this clinical trial.
Szczecin, Poland; Research Site
Lumiliximab with Fludarbine, Cyclophosphamide and Rituximab (FCR) Versus FCR Alone in Subjects with Relapsed Chronic Lymphocytic Leukemia (CLL)
Warszawa, Poland; Research Site
Lumiliximab with Fludarbine, Cyclophosphamide and Rituximab (FCR) Versus FCR Alone in Subjects with Relapsed Chronic Lymphocytic Leukemia (CLL)
Brasov, Romania; Research Site
Lumiliximab with Fludarbine, Cyclophosphamide and Rituximab (FCR) Versus FCR Alone in Subjects with Relapsed Chronic Lymphocytic Leukemia (CLL)
Bucharest, Romania; Research Site
Lumiliximab with Fludarbine, Cyclophosphamide and Rituximab (FCR) Versus FCR Alone in Subjects with Relapsed Chronic Lymphocytic Leukemia (CLL)
Iasi, Romania; Research Site
Lumiliximab with Fludarbine, Cyclophosphamide and Rituximab (FCR) Versus FCR Alone in Subjects with Relapsed Chronic Lymphocytic Leukemia (CLL)
Ekaterinburg, Russia; Research Site
Lumiliximab with Fludarbine, Cyclophosphamide and Rituximab (FCR) Versus FCR Alone in Subjects with Relapsed Chronic Lymphocytic Leukemia (CLL)
Nizhni Novgorod, Russia; Research Site
Lumiliximab with Fludarbine, Cyclophosphamide and Rituximab (FCR) Versus FCR Alone in Subjects with Relapsed Chronic Lymphocytic Leukemia (CLL)
Saratov, Russia; Research Site
Lumiliximab with Fludarbine, Cyclophosphamide and Rituximab (FCR) Versus FCR Alone in Subjects with Relapsed Chronic Lymphocytic Leukemia (CLL)
St. Petersburg, Russia; Research Site
Lumiliximab with Fludarbine, Cyclophosphamide and Rituximab (FCR) Versus FCR Alone in Subjects with Relapsed Chronic Lymphocytic Leukemia (CLL)
Barcelona, Spain; Research Center
If the patient has B-Cell Chronic Lymphocytic Leukemia, has failed treatment with fludarabine, and failed or been intolerant ineligible to treatment with alemtuzumab, he/she may be eligible for this clinical trial.
Barcelona, Spain; Research Site
Lumiliximab with Fludarbine, Cyclophosphamide and Rituximab (FCR) Versus FCR Alone in Subjects with Relapsed Chronic Lymphocytic Leukemia (CLL)
Madrid, Spain; Research Site
Lumiliximab with Fludarbine, Cyclophosphamide and Rituximab (FCR) Versus FCR Alone in Subjects with Relapsed Chronic Lymphocytic Leukemia (CLL)
Murcia, Spain; Research Site
Lumiliximab with Fludarbine, Cyclophosphamide and Rituximab (FCR) Versus FCR Alone in Subjects with Relapsed Chronic Lymphocytic Leukemia (CLL)
Palma de Mallorca, Spain; Research Site
Lumiliximab with Fludarbine, Cyclophosphamide and Rituximab (FCR) Versus FCR Alone in Subjects with Relapsed Chronic Lymphocytic Leukemia (CLL)
Toledo, Spain; Research Site
Lumiliximab with Fludarbine, Cyclophosphamide and Rituximab (FCR) Versus FCR Alone in Subjects with Relapsed Chronic Lymphocytic Leukemia (CLL)
Gothenburg, Sweden; Research Center
If the patient has B-Cell Chronic Lymphocytic Leukemia, has failed treatment with fludarabine, and failed or been intolerant ineligible to treatment with alemtuzumab, he/she may be eligible for this clinical trial.
Linköbing, Sweden; Research Center
If the patient has B-Cell Chronic Lymphocytic Leukemia, has failed treatment with fludarabine, and failed or been intolerant ineligible to treatment with alemtuzumab, he/she may be eligible for this clinical trial.
Lund, Sweden; Research Center
If the patient has B-Cell Chronic Lymphocytic Leukemia, has failed treatment with fludarabine, and failed or been intolerant ineligible to treatment with alemtuzumab, he/she may be eligible for this clinical trial.
Stockholm, Sweden; Research Site
If the patient has B-Cell Chronic Lymphocytic Leukemia, has failed treatment with fludarabine, and failed or been intolerant ineligible to treatment with alemtuzumab, he/she may be eligible for this clinical trial.
Stockholm, Sweden; Research Center
If the patient has B-Cell Chronic Lymphocytic Leukemia, has failed treatment with fludarabine, and failed or been intolerant ineligible to treatment with alemtuzumab, he/she may be eligible for this clinical trial.
Uppsala, Sweden; Research Center
If the patient has B-Cell Chronic Lymphocytic Leukemia, has failed treatment with fludarabine, and failed or been intolerant ineligible to treatment with alemtuzumab, he/she may be eligible for this clinical trial.
Cambridge, United Kingdom; Research Center
If the patient has B-Cell Chronic Lymphocytic Leukemia, has failed treatment with fludarabine, and failed or been intolerant ineligible to treatment with alemtuzumab, he/she may be eligible for this clinical trial.
Leeds, United Kingdom; Research Site
If the patient has B-Cell Chronic Lymphocytic Leukemia, has failed treatment with fludarabine, and failed or been intolerant ineligible to treatment with alemtuzumab, he/she may be eligible for this clinical trial.
Leicester, United Kingdom; Research Center
If the patient has B-Cell Chronic Lymphocytic Leukemia, has failed treatment with fludarabine, and failed or been intolerant ineligible to treatment with alemtuzumab, he/she may be eligible for this clinical trial.
Liverpool, United Kingdom; Research Center
If the patient has B-Cell Chronic Lymphocytic Leukemia, has failed treatment with fludarabine, and failed or been intolerant ineligible to treatment with alemtuzumab, he/she may be eligible for this clinical trial.
London, United Kingdom; Research Site
Lumiliximab with Fludarbine, Cyclophosphamide and Rituximab (FCR) Versus FCR Alone in Subjects with Relapsed Chronic Lymphocytic Leukemia (CLL)
London, United Kingdom; Research Center
If the patient has B-Cell Chronic Lymphocytic Leukemia, has failed treatment with fludarabine, and failed or been intolerant ineligible to treatment with alemtuzumab, he/she may be eligible for this clinical trial.
Nottingham, United Kingdom; Research Site
If the patient has B-Cell Chronic Lymphocytic Leukemia, has failed treatment with fludarabine, and failed or been intolerant ineligible to treatment with alemtuzumab, he/she may be eligible for this clinical trial.
Plymouth, United Kingdom; Research Site
Lumiliximab with Fludarbine, Cyclophosphamide and Rituximab (FCR) Versus FCR Alone in Subjects with Relapsed Chronic Lymphocytic Leukemia (CLL)
Sutton, United Kingdom; Research Center
If the patient has B-Cell Chronic Lymphocytic Leukemia, has failed treatment with fludarabine, and failed or been intolerant ineligible to treatment with alemtuzumab, he/she may be eligible for this clinical trial.
